CinnoPar (teriparatide biosimilar) / CinnaGen - LARVOL DELTA

Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: A single-arm, multi-center study. (PubMed, Bone Rep) - "This study aimed to evaluate the effectiveness of biosimilar teriparatide (CinnoPar®, CinnaGen Co., Iran) in osteoporotic patients after at least one year of treatment...We observed considerable improvements in BMD following treatment with the biosimilar teriparatide for one year or more. The biosimilar teriparatide can be considered as an effective treatment option in female and male patients with osteoporosis."

Journal • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatoid Arthritis • Rheumatology

The efficacy of teriparatide (Cinnopar®) on bone repair in mandibular fractures: A single blinded randomized clinical trial. (PubMed, J Craniomaxillofac Surg) - "Both groups received daily acetaminophen and cephalexin for 1 week. Teriparatide also had no effect on the postoperative complication rate in the control group (P > 0.05). Within the limitations of the study it seems that in mandibular fractures, teriparatide did not affect bone fusion or postoperative complications, so its use is not recommended for better bone fusion and fewer postoperative complications of mandibular fracture during the first month."

Clinical • Journal • Musculoskeletal Diseases • Orthopedics • Pain

A  Phase IV Study of the Safety and Efficacy of CinnoPar in Iranian Patients with Osteoporosis. (PubMed, J Osteoporos) - "Both changes were statistically significant (p < 0.001). Consistent with the findings of previous studies and the drug monograph, no new safety concern was observed with this biosimilar teriparatide, and the drug was effective based on the VAS score and EQ-5D in osteoporotic patients."

Clinical • Journal • P4 data • Back Pain • Musculoskeletal Pain • Osteoporosis • Pain • Rheumatology